This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Medscape, LLC and the American Society of Hematology. Medscape Continuing Medical Education online In conclusion, women receiving chemotherapy for breast cancer have a clinically important risk of VTE, whereas an increased risk of VTE immediately after endocrine therapy is restricted to tamoxifen.
![aa 1210 november 11 2015 aa 1210 november 11 2015](https://www.frontiersin.org/files/Articles/592588/fgene-11-592588-HTML/image_m/fgene-11-592588-g001.jpg)
Risk of VTE was noticeably higher in the 3 months after initiation of tamoxifen compared with the risk before therapy (HR, 5.5 95% CI, 2.3-12.7 AR, 24.1) however, initiating therapy with aromatase inhibitors was not associated with VTE (HR, 0.8 95% CI, 0.5-1.4 AR, 28.3). After surgery, the risk was significantly increased in the first month (hazard ratio, 2.2 95% CI, 1.4-3.4 AR, 23.5 reference group, no surgery), but the risk was not increased after the first month. person-years) than that in women who did not receive chemotherapy. Women had an annual VTE incidence of 6% while receiving chemotherapy which was 10.8-fold higher (95% confidence interval, 8.2-14.4 absolute rate, 59. Cox regression analysis was performed to determine which demographic, treatment-related, and biological factors independently affected VTE risk. Our cohort comprised 13 202 patients with breast cancer from the Clinical Practice Research Datalink (linked to Hospital Episode Statistics and Cancer Registry data) diagnosed between 19 with follow-up continuing to the end of 2010.
![aa 1210 november 11 2015 aa 1210 november 11 2015](https://www.mdpi.com/minerals/minerals-11-00379/article_deploy/html/images/minerals-11-00379-g015.png)
We aimed to determine the impact of breast cancer stage, biology, and treatment on the absolute and relative risks of VTE by using several recently linked data sources from England.
![aa 1210 november 11 2015 aa 1210 november 11 2015](https://volcano.si.edu/images/bulletin/211040/211040_BGVN_206.jpg)
However, no previous epidemiologic studies have investigated the relative impact of breast cancer treatments in a time-dependent manner. Patients with breast cancer are at increased risk of venous thromboembolism (VTE), particularly in the peridiagnosis period.